CIA: Drug Enforcement Administration China Country Brief
This is a declassified Drug Enforcement Administration China Country Brief, dated February five, two thousand four. The brief appears in the public record as a non‑classified intelligence briefing on the People's Republic of China, and it is notable for its detailed assessment of drug‑related activity across the nation.
- Date
- JUL 31 · 2026
- Release
- Declassified · U.S. public record (FOIA)
- Source document
- View the primary source document
Episode notes
This is a declassified Drug Enforcement Administration China Country Brief, dated February five, two thousand four. The brief appears in the public record as a non‑classified intelligence briefing on the People's Republic of China, and it is notable for its detailed assessment of drug‑related…
Questions about this case
- What was CIA: Drug Enforcement Administration China Country Brief about?
- This is a declassified Drug Enforcement Administration China Country Brief, dated February five, two thousand four. The brief appears in the public record as a non‑classified intelligence briefing on the People's Republic of China, and it is notable for its detailed assessment of drug‑related activity across the nation.
- Why was this case declassified?
- This material entered the public record through the U.S. declassification and Freedom of Information Act (FOIA) process. Storyflo narrates it directly from the public release.
Related cases
- Case · ARCHIVE-001
Central Intelligence Agency Memorandum Dated October Twenty‑six, Nineteen
- Case · ARCHIVE-002
NSA Department Of The Army Memorandum On Chinese Prisoners Of War, Dated October
- Case · ARCHIVE-003
NSA Chinese Communist Order Of Battle, Department Of The Army, Thirty‑fifth
- Case · ARCHIVE-004
United States Intelligence Cable Reporting On Chinese Intentions Toward
- Case · ARCHIVE-005
Today On Declassified, We Examine A Memorandum From The Department Of State
Get the next declassified case in your inbox
A short dispatch when a new file is released — narrated, answer-first, and linked straight to the primary source. No spam; unsubscribe anytime.